Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. BELLUS Health Inc.
  6. News
  7. Summary
    BLU   CA07987C2040

BELLUS HEALTH INC.

(BLU)
  Report
Delayed Toronto Stock Exchange  -  05/20 04:00:00 pm EDT
10.59 CAD   -2.58%
05/11BELLUS : Q1 Earnings Snapshot
AQ
05/11Bellus Health Reports Q1 Net Loss of US$14.4 Million, Provides Update
MT
05/11BELLUS Health Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

RBC Capital Keeps Outperform/Speculative Risk Rating, US$14 TP on Bellus Health

01/11/2022 | 01:08pm EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
BELLUS HEALTH INC. -2.58% 10.59 Delayed Quote.4.13%
ON SEMICONDUCTOR CORPORATION -1.33% 55.76 Delayed Quote.-16.87%
All news about BELLUS HEALTH INC.
05/11BELLUS : Q1 Earnings Snapshot
AQ
05/11Bellus Health Reports Q1 Net Loss of US$14.4 Million, Provides Update
MT
05/11BELLUS Health Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/11Earnings Flash (BLU.TO) BELLUS HEALTH Says Ended Q1 2022 with US$234.0 million in cash,..
MT
05/11Earnings Flash (BLU.TO) BELLUS HEALTH Posts Q1 Basic and Diluted Loss US$0.13
MT
05/11BELLUS Health Reports First Quarter 2022 Financial Results and Business Highlights
BU
05/11TRANSCRIPT : BELLUS Health Inc. - Shareholder/Analyst Call
CI
05/02BELLUS HEALTH : to Present Late-Breaking Clinical Data from the Phase 2b SOOTHE Trial of B..
PU
05/02BELLUS Health to Present Late-Breaking Clinical Data from the Phase 2b SOOTHE Trial of ..
BU
05/02BELLUS Health to Present Late-Breaking Clinical Data from the Phase 2b SOOTHE Trial of ..
CI
More news
Analyst Recommendations on BELLUS HEALTH INC.
More recommendations
Financials
Sales 2022 0,34 M 0,26 M 0,26 M
Net income 2022 -103 M -80,3 M -80,3 M
Net Debt 2022 - - -
P/E ratio 2022 -11,6x
Yield 2022 -
Capitalization 1 130 M 885 M 885 M
Capi. / Sales 2022 3 353x
Capi. / Sales 2023 881x
Nbr of Employees 40
Free-Float 81,2%
Chart BELLUS HEALTH INC.
Duration : Period :
BELLUS Health Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BELLUS HEALTH INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 10,59 CAD
Average target price 18,50 CAD
Spread / Average Target 74,7%
EPS Revisions
Managers and Directors
Roberto Bellini President, Chief Executive Officer & Director
Ramzi Benamar Chief Financial Officer
Francesco Bellini Chairman
Denis Garceau Chief Scientific Officer
Catherine M. Bonuccelli Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
BELLUS HEALTH INC.4.13%881
GILEAD SCIENCES, INC.-12.08%80 075
REGENERON PHARMACEUTICALS, INC.4.69%71 235
VERTEX PHARMACEUTICALS17.76%66 136
WUXI APPTEC CO., LTD.-16.92%42 735
BIONTECH SE-36.77%39 612